- Home
- KLRS vs LONA Comparison
KLRS vs LONA Comparison
Compare KLRS & LONA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KLRS | LONA |
|---|---|---|
| Founded | 2019 | 2011 |
| Country | United States | United States |
| Employees | N/A | 26 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.0M | 53.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | KLRS | LONA |
|---|---|---|
| Price | $9.78 | $6.58 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $20.67 | $10.00 |
| AVG Volume (30 Days) | ★ 58.8K | 52.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.14 | $4.21 |
| 52 Week High | $11.90 | $6.61 |
Technical Indicators
Market Signals| Indicator | KLRS | LONA |
|---|---|---|
| Relative Strength Index (RSI) | 48.74 | 61.24 |
| Support Level | $8.08 | $4.34 |
| Resistance Level | $10.64 | N/A |
| Average True Range (ATR) | 0.90 | 0.51 |
| MACD | -0.10 | 0.11 |
| Stochastic Oscillator | 29.18 | 84.70 |
Price Performance
Historical ComparisonAbout KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
About LONA LeonaBio Inc. Common Stock
LeonaBio Inc is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS).